Lilly’s Basal Insulin Peglispro Outperforms Lantus® in HbA1c Superiority in Phase III Trials For Type 1 Diabetes
News, Type 1 Diabetes News
Eli Lilly and Company recently reported that its IMAGINE-1 and IMAGINE-3 Phase III clinical trials showed that basal insulin peglispro (BIL) treatment induces a statistically significant lower hemoglobin A1c (HbA1c, glycated haemoglobin), a ... Read more